Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
NCT06715020Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of [68Ga]Ga-TTP in breast cancer (2 cohorts), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Diagnostic performance of [68Ga]Ga-TTP PET compared with [18F]FDG PET at 2 months and Change in [68Ga]Ga-TTP uptake in relation to ADC treatment response at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
[68Ga]Ga-TTP
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06715020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715020.